Coagulation disorders and an immune-altered state are common among total artificial heart patients. In this context, we sought to evaluate the safety of percutaneous dilatational tracheostomy in cases of prolonged need for mechanical ventilatory support. We retrospectively analysed the charts of 11 total artificial heart patients who received percutaneous dilatational tracheostomy. We focused on early and late complications. We observed no major complications and no procedure-related deaths. Early minor complications included venous oozing (45.4%) and one case of local infection. Late complications, including subglottic stenosis, stomal infection or infections of the lower respiratory tract, were not observed. In conclusion, percutaneous dilatational tracheostomy in total artificial heart patients is safe. Considering the well-known benefits of early tracheotomy over prolonged translaryngeal intubation, we advocate early timing of therapy in cases of prolonged mechanical ventilation.
INTRODUCTION
Percutaneous dilatational tracheostomy (PDT) is an established option for the management of critically ill patients requiring prolonged mechanical ventilatory support [1] . In the special subset of patients with end-stage biventricular heart failure requiring total artificial heart (TAH) implantation, PDT is performed under coagulopathic and immune-altered conditions: impaired peripheral perfusion and increased filling pressures in the preoperative setting result in hepatic dysfunction and coagulation disorders [2] . Complement activation and cytokine release resulting from interaction between device surfaces and blood predispose patients to infection and inflammation [3] . With this study, we sought to evaluate the safety of PDT in TAH patients.
METHODS
Ethical committee approval was not necessary. Informed patient consent regarding the procedure and the collection and publication of the data was obtained. Between July 2011 and January 2015, PDT was performed in 10 male and 1 female Caucasian patients with a SynCardia-TAH (SynCardia Systems, Inc., Tucson, AZ, USA) due to inability to wean from mechanical ventilation. See Table 1 for patient demographics. PDT was performed with bronchoscopic guidance, at 7 days (median value; range 6-12 days), using a standard PDT set (Tracoe Medical GmbH, Nieder-Olm, Germany) as already described by others [4] . Since all patients were in the ICU, no warfarin was administered. Heparin was used instead with a target PTT of 50-60 s. Prior to the procedure, intravenous heparin administration was discontinued and severe thrombocytopaenia was corrected.
RESULTS
Results of retrospective analysis are listed in Table 2 . PDT indications were general weakness due to cardiac cachexia (45.4%), multiorgan failure (36.4%), recurrent left pulmonary total atelectasis (9.1%) and severe respiratory failure on the grounds of an adult respiratory distress syndrome requiring concomitant veno-venous extracorporeal membrane oxygenation (9.1%). Procedural time was 10 min (median value; range 7-15 min). Although the procedure was performed mainly under coagulopathic conditions (International normalized ratio median: 1.9; range: 1.3-2.9/partial thromboplastin time median 55 s; range: 45-62/total platelet count median: 125 000/μl; range: 90 000-197 000/μl), there were no cases of major bleeding requiring surgical intervention. Minor venous oozing (45.4%) and one case of local infection in the tracheostomy site successfully treated with antibiotics were the only early complications observed. There were no procedure-related deaths and no cases of mediastinitis. Following PDT, median duration of ventilation was 20.9 days (range 3.7-98.5). In 1 patient, therapy is still ongoing. In the remaining 10 patients, 4 were weaned from mechanical ventilation, decannulated and finally discharged home (in-hospital stay median: 130 days; range: 114-135). In these patients, late complications, including subglottic stenosis, stomal infection or infections of the lower respiratory tract, were not observed. Not surprisingly, overall mortality was relatively high. This was associated with multiorgan failure, which as stated before [5] is relatively common among TAH patients in need of prolonged ventilatory support.
CONCLUSIONS
In this study, we examined the safety of PDT in patients requiring TAH therapy for the treatment of end-stage biventricular heart failure. We demonstrated that despite an extremely coagulopathic and immune-altered state, bleeding and infectious complications are rare. Considering the well-known benefits of early tracheotomy over prolonged translaryngeal intubation [6] , we advocate performing PDT at an early stage of therapy in cases of prolonged mechanical ventilation following TAH implantation.
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